Vol 9 (September 30, 2024): Annals of Blood

Editorial Commentary 
Olverembatinib for the treatment of chronic myeloid leukemia in chronic phase
Emaan Ul Haque, Elias Jabbour, Jayastu Senapati, Fadi G. Haddad
Annals of Blood  
2024;
9:
27  
Brief Report 
Limited potential of sheep as a large animal to model transfusion-related acute lung injury mediated by antibodies against human neutrophil antigen 3a
Filip Radenkovic, Mark Burton, Penny Hassell, Sara Chiaretti, Xuan Bui, Shen Zhao, Martina Jones, Robert Flower, John-Paul Tung
Annals of Blood  
2024;
9:
26  
Review Article 
Advancing through challenges: current strategies in sickle cell disease management
Sheinei Alan, Sebastian R. Mendez-Marti, Chad Zik, William B. Ershler
Annals of Blood  
2024;
9:
25  
Original Article 
Predictive Model of variable laboratory findings calculation and monitoring during plasmapheresis procedures
Zivile Jacike, Ema Rajackaite, Ramune Sepetiene, Ninette Robbins, Mohamed Ali
Annals of Blood  
2024;
9:
24  
Original Article 
Immune thrombocytopenia exacerbation post COVID-19 vaccination: a systematic review and meta-analysis
Wei Xuan Chue, Livia Anjaneth Lienardi, Titus Qi Wei Tan, Insyirah Abdul Kadir, Joyce Ching Mei Lam
Annals of Blood  
2024;
9:
23  
Editorial 
Preface to the special series “Blood Transfusion Practice in ECMO Patients”
Devan Kowdley, Gennaro Martucci
Annals of Blood  
2024;
9:
22  
Editorial 
RH alleles: historical milestones, molecular advances, and clinical application
Carine Prisco Arnoni, Emilia Sippert, Maria Rios
Annals of Blood  
2024;
9:
21